Abstract 4367257: Biomarkers in Cardiac Arrest: An Analysis from the Critical Care Cardiology Trials Network

Background: Current clinical tools and biomarkers have limited predictive performance for neurological outcomes after cardiac arrest. Novel biomarkers, including kynureninase (KYNU), have the potential to improve neuro-prognostication. Limited data suggest a potential association of KYNU, a key enzyme in tryptophan metabolism, with poor neurological outcome following cardiac arrest. Methods: Patients admitted to the cardiac intensive care unit (CICU) at Brigham and Women’s Hospital (Boston, MA; 2017-2020) were enrolled in a biorepository with admission blood sampling. In-hospital neurological outcome, including modified Rankin score (mRS), was assessed by structured chart review. KYNU was assayed using the Olink platform (Neurology panel). We performed a case-control study among patients with (n=150) and without (n=81) presenting cardiac arrest and adjusted for age, sex, BMI, eGFR, glial fibrillary acid protein, and the presence of shock. In addition, we evaluated the association between KYNU and poor neurological outcome and mortality among the cohort with cardiac arrest. Results: Overall, KYNU concentration was significantly associated with cardiogenic shock on admission (p<0.001). KYNU was significantly associated with presenting cardiac arrest with a strong graded relationship across KYNU quartiles in patients with and without shock ( Fig 1 ). Among patients with cardiac arrest, higher presenting KYNU concentration was associated with a pattern of higher risk of poor neurological outcome at discharge ( Fig 2 ). KYNU was also significantly associated with mortality (Q4 vs. Q1: OR 2.89; 95% CI 1.13-7.70; p=0.029). Conclusions: KYNU concentrations are elevated following cardiac arrest, and higher concentrations are associated with death and have a tendency toward poor neurological outcomes among patients with cardiac arrest. These data highlight the potential for KYNU as a novel biomarker to inform neuro-prognostication following cardiac arrest.

Authors

Institutions

Publication Details

Journal
Circulation
Published
2025-11-03
DOI
https://doi.org/10.1161/circ.152.suppl_3.4367257
Primary Topic
Tryptophan and brain disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Abstract 4367257: Biomarkers in Cardiac Arrest: An Analysis from the Critical Care Cardiology Trials Network

Erin A. Bohula, Sarah A. Morrow, Sauyeh K. Zamani, Andrea Bellavia et al.
Circulation
Tryptophan and brain disorders
article

Abstract 4367257: Biomarkers in Cardiac Arrest: An Analysis from the Critical Care Cardiology Trials Network

Erin A. Bohula, Sarah A. Morrow, Sauyeh K. Zamani, Andrea Bellavia, David Van Den Berg
article en

Abstract

Background: Current clinical tools and biomarkers have limited predictive performance for neurological outcomes after cardiac arrest. Novel biomarkers, including kynureninase (KYNU), have the potential to improve neuro-prognostication. Limited data suggest a potential association of KYNU, a key enzyme in tryptophan metabolism, with poor neurological outcome following cardiac arrest. Methods: Patients admitted to the cardiac intensive care unit (CICU) at Brigham and Women’s Hospital (Boston, MA; 2017-2020) were enrolled in a biorepository with admission blood sampling. In-hospital neurological outcome, including modified Rankin score (mRS), was assessed by structured chart review. KYNU was assayed using the Olink platform (Neurology panel). We performed a case-control study among patients with (n=150) and without (n=81) presenting cardiac arrest and adjusted for age, sex, BMI, eGFR, glial fibrillary acid protein, and the presence of shock. In addition, we evaluated the association between KYNU and poor neurological outcome and mortality among the cohort with cardiac arrest. Results: Overall, KYNU concentration was significantly associated with cardiogenic shock on admission (p<0.001). KYNU was significantly associated with presenting cardiac arrest with a strong graded relationship across KYNU quartiles in patients with and without shock ( Fig 1 ). Among patients with cardiac arrest, higher presenting KYNU concentration was associated with a pattern of higher risk of poor neurological outcome at discharge ( Fig 2 ). KYNU was also significantly associated with mortality (Q4 vs. Q1: OR 2.89; 95% CI 1.13-7.70; p=0.029). Conclusions: KYNU concentrations are elevated following cardiac arrest, and higher concentrations are associated with death and have a tendency toward poor neurological outcomes among patients with cardiac arrest. These data highlight the potential for KYNU as a novel biomarker to inform neuro-prognostication following cardiac arrest.

CirculationVol. 152(Suppl_3)
Brigham and Women's Hospital (US), Harvard University (US)
Openalex Percentile: Top 67%
Tryptophan and brain disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.